Key result
Apixaban BID yields supratherapeutic peak levels in ~30% of peritoneal dialysis patients.
Why the study?
The efficacy and safety profile of apixaban remains uncertain in patients receiving peritoneal dialysis despite increasing use in this population.
Does a reduced dose of apixaban (2.5 mg twice daily) result in safe and therapeutic pharmacokinetic levels in peritoneal dialysis patients with atrial fibrillation?
Observational (n=10)
No
Does a reduced dose of apixaban (2.5 mg twice daily) result in safe and therapeutic pharmacokinetic levels in peritoneal dialysis patients with atrial fibrillation?
Even at a reduced dose of 2.5 mg twice daily, apixaban can lead to supratherapeutic drug levels in peritoneal dialysis patients, highlighting the need for therapeutic drug monitoring or extreme caution.
Answers are grounded in this paper and cite their sources.
May warrant caution or TDM with reduced-dose apixaban in PD; hypothesis-generating for AF dosing and needs prospective validation.
Rationale & Objective: The efficacy and safety profile of apixaban remains uncertain in patients receiving peritoneal dialysis (PD) despite increasing use in this population. Accordingly, we assessed the pharmacokinetics of apixaban among patients receiving PD. Study Design: A pharmacokinetics study in a single center. Patients recruited received 1 week of apixaban at 2.5 mg twice a day to reach steady state. Serial blood samples were then taken before and after the last dose for pharmacokinetics analysis of apixaban. Setting & Participants: Ten stable PD patients with atrial fibrillation in an outpatient setting. Analytical Approach/Outcomes: Pharmacokinetic parameters including the area under the concentration-time curve from time 0 to 12 hours after the last dose of apixaban (AUC0-12), peak concentration, trough level, time to peak apixaban concentration, half-life, and drug clearance were analyzed. Results: for the PD group was significantly higher than those reported previously for hemodialysis patients or healthy individuals. Three patients had a supratherapeutic peak concentration whereas 2 patients had a supratherapeutic trough level as compared with the pharmacokinetic parameter in healthy individuals taking equivalent therapeutic dosage. Limitations: Small sample size with short study duration limits the ability to ascertain the true bleeding risk and to detect any clinical outcomes. Results may be limited to Asian populations only. Conclusions: A proportion of PD patients had supratherapeutic levels even when the reduced dosage 2.5 mg twice a day was used. Given the large interindividual variation in the drug level, therapeutic drug monitoring should be done if available. Otherwise, one should start the drug at reduced doses with caution and with more frequent clinical monitoring for any signs of bleeding.
No takes yet. Share an insight, caveat, or question.
Fung et al. (2023) conducted an observational in Atrial fibrillation in peritoneal dialysis patients (n=10). Apixaban vs. Previously reported hemodialysis patients or healthy individuals was evaluated on Pharmacokinetic parameters including AUC0-12, peak concentration, trough level, time to peak, half-life, and drug clearance. Apixaban twice daily in peritoneal dialysis patients resulted in supratherapeutic peak concentrations in 3 of 10 patients and supratherapeutic trough levels in 2 of 10 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: